Amgen asset from $27.8B Horizon buy scores in Phase 3 Sjögren's study

Amgen is awaiting another Phase 3 readout for the investigational Sjögren's disease therapy, set for later this year. William Blair anticipates that at least two trials will be needed to support an FDA application.